Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H17NO3 |
Molecular Weight | 211.2576 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)C1=CC=C(O)C(O)=C1
InChI
InChIKey=JWZZKOKVBUJMES-UHFFFAOYSA-N
InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
Molecular Formula | C11H17NO3 |
Molecular Weight | 211.2576 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/cdi/isoproterenol.html | https://www.ncbi.nlm.nih.gov/pubmed/209581 | https://www.ncbi.nlm.nih.gov/pubmed/22073124 | https://www.ncbi.nlm.nih.gov/pubmed/11723224
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/cdi/isoproterenol.html | https://www.ncbi.nlm.nih.gov/pubmed/209581 | https://www.ncbi.nlm.nih.gov/pubmed/22073124 | https://www.ncbi.nlm.nih.gov/pubmed/11723224
Isoproterenol (trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma. Isoproterenol is a non-selective β adrenoreceptor agonist and TAAR1 agonist that is the isopropylaminomethyl analog of epinephrine. Isoprenaline's effects on the cardiovascular system (non-selective) relate to its actions on cardiac β1 receptors and β2 receptors on smooth muscle within the tunica media of arterioles. Isoprenaline has positive inotropic and chronotropic effects on the heart. β2 adrenoceptor stimulation in arteriolar smooth muscle induces vasodilation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure. The overall effect is to decrease mean arterial pressure due to the β2 receptors' vasodilation. The adverse effects of isoprenaline are also related to the drug's cardiovascular effects. Isoprenaline can produce tachycardia (an elevated heart rate), which predisposes patients to cardiac arrhythmias.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5857 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22073124 |
|||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22182578 |
240.0 nM [EC50] | ||
Target ID: CHEMBL246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26125514 |
86.0 nM [IC50] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19581100 |
12.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ISOPROTERENOL HYDROCHLORIDE Approved UseIsoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) Launch Date1956 |
|||
Primary | ISOPROTERENOL HYDROCHLORIDE Approved UseIsoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) Launch Date1956 |
|||
Primary | ISOPROTERENOL HYDROCHLORIDE Approved UseIsoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) Launch Date1956 |
|||
Primary | ISOPROTERENOL HYDROCHLORIDE Approved UseIsoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) Launch Date1956 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7422709 |
0.3 mg/kg single, subcutaneous dose: 0.3 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
ISOPROTERENOL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 1 times / day multiple, respiratory (max) Studied dose Dose: 15 mg, 1 times / day Route: respiratory Route: multiple Dose: 15 mg, 1 times / day Sources: Page: p.642 |
unhealthy, 27 - 67 n = 12 Health Status: unhealthy Condition: Bronchial asthma Age Group: 27 - 67 Sex: M+F Population Size: 12 Sources: Page: p.642 |
Other AEs: Tachycardia, Premature ventricular contractions... Other AEs: Tachycardia (66.7%) Sources: Page: p.642Premature ventricular contractions (8.3%) |
0.2 mg multiple, intravenous (max) Recommended Dose: 0.2 mg Route: intravenous Route: multiple Dose: 0.2 mg Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Heart block|Adams-Stokes attacks|Cardiac arrest Sources: Page: p.2 |
Disc. AE: Block heart, Adams-Stokes syndrome... AEs leading to discontinuation/dose reduction: Block heart Sources: Page: p.2Adams-Stokes syndrome |
1 mg multiple, intramuscular (max) Recommended Dose: 1 mg Route: intramuscular Route: multiple Dose: 1 mg Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Heart block|Adams-Stokes attacks|Cardiac arrest Sources: Page: p.2 |
Disc. AE: Block heart, Adams-Stokes syndrome... AEs leading to discontinuation/dose reduction: Block heart Sources: Page: p.2Adams-Stokes syndrome |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Tachycardia | 66.7% | 15 mg 1 times / day multiple, respiratory (max) Studied dose Dose: 15 mg, 1 times / day Route: respiratory Route: multiple Dose: 15 mg, 1 times / day Sources: Page: p.642 |
unhealthy, 27 - 67 n = 12 Health Status: unhealthy Condition: Bronchial asthma Age Group: 27 - 67 Sex: M+F Population Size: 12 Sources: Page: p.642 |
Premature ventricular contractions | 8.3% | 15 mg 1 times / day multiple, respiratory (max) Studied dose Dose: 15 mg, 1 times / day Route: respiratory Route: multiple Dose: 15 mg, 1 times / day Sources: Page: p.642 |
unhealthy, 27 - 67 n = 12 Health Status: unhealthy Condition: Bronchial asthma Age Group: 27 - 67 Sex: M+F Population Size: 12 Sources: Page: p.642 |
Adams-Stokes syndrome | Disc. AE | 0.2 mg multiple, intravenous (max) Recommended Dose: 0.2 mg Route: intravenous Route: multiple Dose: 0.2 mg Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Heart block|Adams-Stokes attacks|Cardiac arrest Sources: Page: p.2 |
Block heart | Disc. AE | 0.2 mg multiple, intravenous (max) Recommended Dose: 0.2 mg Route: intravenous Route: multiple Dose: 0.2 mg Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Heart block|Adams-Stokes attacks|Cardiac arrest Sources: Page: p.2 |
Adams-Stokes syndrome | Disc. AE | 1 mg multiple, intramuscular (max) Recommended Dose: 1 mg Route: intramuscular Route: multiple Dose: 1 mg Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Heart block|Adams-Stokes attacks|Cardiac arrest Sources: Page: p.2 |
Block heart | Disc. AE | 1 mg multiple, intramuscular (max) Recommended Dose: 1 mg Route: intramuscular Route: multiple Dose: 1 mg Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Heart block|Adams-Stokes attacks|Cardiac arrest Sources: Page: p.2 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18725507/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18725507/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18725507/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Myocardial DNA and cell count following isoproterenol-induced myocardial necrosis in the rat]. | 1975 |
|
Electrophysiologic studies in the denervated transplanted human heart. II. Response to norepinephrine, isoproterenol and propranolol. | 1975 Dec |
|
[Pharmacology of acebutolol in animals]. | 1975 Dec 31 |
|
Effects of prindolol on isoproterenol-induced subendocardial ischaemia in dogs with multiple chronic coronary artery occlusion. | 1975 Jul |
|
The use of practolol in supraventricular arrhythmias associated with acute illnesses. | 1975 May |
|
Metabolic responses following isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs. non-arteriosclerotic virgin and ovariectomized female rats. | 1975 May-Jun |
|
Metabolic responses to catecholamines. | 1976 |
|
Spin-spin relaxation times in myocardial hypertrophy induced by endocrine agents in rat. | 1998 Dec |
|
Activity of Na+/K+-ATPase and of Ca++-ATPase under the action of adenosine triphosphate in experimental myocardial hypertrophy. | 1998 Jul-Dec |
|
Sensitivity to orthostatic stress and beta-receptor activation in patients with isoproterenol-induced vasovagal syncope: a case controlled study. | 1999 Apr |
|
Antioxidant activity of AO-8, a herbal formulation in vitro and in vivo experimental models. | 1999 Jun |
|
Effects of isoproterenol on myocardial structure and function in septic rats. | 1999 Mar |
|
Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers. | 1999 May |
|
Catecholamines participate in the induction of ornithine decarboxylase gene expression in normal and hyperplastic mouse kidney. | 1999 May 31 |
|
Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. | 1999 Nov |
|
Differential expression of small heat shock proteins in reactive astrocytes after focal ischemia: possible role of beta-adrenergic receptor. | 1999 Nov 15 |
|
Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol-induced heart failure in the rat. | 1999 Nov-Dec |
|
In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors. | 1999 Oct 15 |
|
Lipolysis is an important determinant of isoproterenol-induced myocardial necrosis. | 1999 Sep-Oct |
|
Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues. | 2000 Apr 20 |
|
Recurrent asystoles associated with vasovagal reaction during venipuncture. | 2000 Dec |
|
Low catecholamine concentrations protect adult rat ventricular myocytes against apoptosis through cAMP-dependent extracellular signal-regulated kinase activation. | 2000 Dec |
|
Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat. | 2000 Jun |
|
Mitochondrial oligomycin-sensitive ATPase during isoproterenol-induced cell injury of myocardium. | 2000 Mar-Apr |
|
Isoproterenol-induced hypertrophy may result in distinct left ventricular changes. | 2000 May-Jun |
|
Effect of SMP-300, a new Na+/H+ exchange inhibitor, on myocardial ischemia and experimental angina models in rats. | 2000 Oct |
|
Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. | 2000 Sep |
|
Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis. | 2000 Sep-Oct |
|
Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system. | 2001 |
|
Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system. | 2001 Apr |
|
Elevated parasympathetic nerve tone in isoproterenol-induced neurally mediated syncope during head-up tilt testing. | 2001 Apr |
|
Effects of alpha- and beta-adrenergic stimulation on free magnesium concentrations in platelets from healthy and obese individuals. | 2001 Dec |
|
Paroxysmal tachycardia in children and teenagers with normal sinus rhythm and without heart disease. | 2001 Jan |
|
Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. | 2001 Jul |
|
Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal. | 2001 Mar 2 |
|
Cardioprotective effects of Picrorrhiza kurroa against isoproterenol-induced myocardial stress in rats. | 2001 May |
|
Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats. | 2002 Feb |
|
Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats. | 2002 Jan |
|
Glucose uptake via SGLT-1 is stimulated by beta(2)-adrenoceptors in the ruminal epithelium of sheep. | 2002 Jun |
|
Vanillylamide-based propanolamine derivative displays alpha/beta-adrenoceptor blocking and vasodilating properties. | 2002 Jun |
Patents
Sample Use Guides
Bolus intravenous injection: 0.02 mg to 0.06 mg; Intravenous infusion: 5 mcg/min; Intramuscular 0.2 mg; Subcutaneous 0.2 mg; Intracardiac 0.02 mg;
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22073124
Human embryonic kidney cells (HEK293) were cultured in Minimum Essential Medium (MEM) Earle’s (Biochrom AG) supplemented with 10% FBS (PAA Laboratories GmbH), 100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom AG) and 2 mM L-glutamine (Invitrogen) at 37C with 5% CO2. 48 well plates were coated with Poly-L-Lysine (Biochrom) and HEK293 cells were seeded with 37,500 cells per well. Transient transfection in triplicates with 84 ng DNA/well using metafectene according to manufactures instructions (Biontex, Munich, Germany) was performed 28 hours later. 40 hours after transfection cells were pre-incubated for 5 minutes with stimulation buffer containing of MEM Earle’s media and 1 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma). This stimulation buffer was used for all further steps. For ligand competition experiments cells were incubated with tyramine, 2-phenylethylamine or octopamine ranging from 6.7 nM to 6700 nM, diluted in stimulation buffer for 15 minutes followed by a stimulation with isoprenaline in concentrations ranging from 1 nM to 10000 nM for 30 minutes. All reactions were performed at 37C with 5% CO2 saturated air and stopped by aspirating medium.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:27:16 GMT 2023
by
admin
on
Sat Dec 16 16:27:16 GMT 2023
|
Record UNII |
L628TT009W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01CA02
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-ATC |
C01CA02
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-ATC |
R03AK02
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
NDF-RT |
N0000175555
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
NDF-RT |
N0000000245
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-ATC |
R03CB01
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-ATC |
R03AB02
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-VATC |
QR03AB02
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-VATC |
QR03CB01
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-VATC |
QR03AK02
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-VATC |
QR03CB51
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
||
|
WHO-ATC |
R03CB51
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000087152
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL434
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
D007545
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
1499
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
9975
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
ISOPRENALINE
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
7683-59-2
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
DB01064
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
64317
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
3779
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
m6533
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
L628TT009W
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
6054
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
536
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
SUB08330MIG
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
DTXSID4023175
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
33791
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
m6533
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
231-687-7
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
C62041
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
4201
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY | |||
|
L628TT009W
Created by
admin on Sat Dec 16 16:27:18 GMT 2023 , Edited by admin on Sat Dec 16 16:27:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
ENANTIOMER -> RACEMATE |
|
||
|
TARGET -> AGONIST |
Assay in chinese hamster ovary (CHO) cells stably expressing the three β-adrenergic receptor subtypes at comparable leve50 to 80 pM 125I-CYP were used as radioligand. Experiments were done in the presence of 100 µM GTP.
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|